|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Southwest Oncology Group |
|---|---|
| Collaborators: |
National Cancer Institute (NCI) Eastern Cooperative Oncology Group |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00003292 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of ifosfamide in treating patients with meningeal tumors that have recurred or that cannot be removed surgically.
| Condition | Intervention | Phase |
|---|---|---|
|
Chondrosarcoma Adult Fibrosarcoma Adult Leiomyosarcoma Adult Rhabdomyosarcoma Adult Malignant Meningioma Adult Brain Malignant Hemangiopericytoma |
Drug: ifosfamide Procedure: chemotherapy |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Phase II Study of Ifosfamide in Patients With Aggressive Meningeal Tumors |
OBJECTIVES:
OUTLINE: All patients receive ifosfamide IV continuously over 72 hours on days 1-3 of each 21 day treatment course. Patients are evaluated for response/progression after every 2 courses. Patients with stable disease receive up to 8 courses of therapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, then every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 35 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations
Show 70 Study Locations| Study Chair: | Leslie McAllister, MD | Neurological Clinic |
| Study Chair: | Lynn G. Feun, MD | University of Miami Sylvester Comprehensive Cancer Center |
More Information
| Study ID Numbers: | CDR0000066225, SWOG-S9624, E-S9624, NABTT-S9624 |
| Study First Received: | November 1, 1999 |
| Last Updated: | January 11, 2007 |
| ClinicalTrials.gov Identifier: | NCT00003292 History of Changes |
| Health Authority: | United States: Federal Government |
|
Fibrosarcoma Neoplasms, Muscle Tissue Meningeal Neoplasms Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Leiomyosarcoma Neoplasms, Nerve Tissue Central Nervous System Neoplasms Neoplasms, Connective and Soft Tissue Neoplasms by Site Therapeutic Uses Chondrosarcoma Neoplasms, Vascular Tissue Meningioma Alkylating Agents |
Nervous System Neoplasms Rhabdomyosarcoma Neoplasms by Histologic Type Myosarcoma Nervous System Diseases Hemangiopericytoma Pharmacologic Actions Neoplasms Ifosfamide Sarcoma Neoplasms, Connective Tissue Antineoplastic Agents, Alkylating Neoplasms, Fibrous Tissue Isophosphamide mustard |